TrovaGene, Inc. (NASDAQ:TROV)

CAPS Rating: 1 out of 5

TROV News and Commentary

Caps

How do you think TROV will perform against the market?

Add Stock to CAPS Watchlist

All Players

31 Outperform
5 Underperform
 

All-Star Players

1 Outperform
4 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top TROV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

TROV VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about TROV.

Recs

0
Member Avatar gafftm14 (56.54) Submitted: 5/2/2017 6:10:55 PM : Outperform Start Price: $0.91 TROV Score: -19.28

great space.. just had a large pull back and could be primed to rebound

Recs

0
Member Avatar DavidLTalbot (< 20) Submitted: 6/12/2015 8:12:43 AM : Outperform Start Price: $13.49 TROV Score: -115.64

Been in since $5.89, worked out very well so far. Still a deep speculation play based on positive results for cancer mutation monitoring at several of the top cancer specialty hospitals. The key questions are:
1) Commercialization of the cancer mutation monitoring products (they have a few different ones for different cancers) which so far have been proven more effective than biopsies (urine sample versus cutting patient open, big diff) If this works out, this alone could justify a 750m market cap
2) Potentially creating and commercializing broader use urine tests like HPV (in testing) and potentially general cancer screenings for some of the hardest to detect killer cancers like pancreatic or lung cancers. This is further a-field speculation but if this part of the thesis works out it could justify a vastly higher market cap.

Like any speculative biotech play, you're either in for 10x or going to zero so not for the faint of heart.

Recs

0
Member Avatar ciabia (< 20) Submitted: 4/22/2015 9:23:13 PM : Outperform Start Price: $8.64 TROV Score: -112.58

non-invasive tests which have a huge market potentials. Issues with diagnostic reimbursement may cause issues, but upside seems very good.

Leaderboard

Find the members with the highest scoring picks in TROV.

Score Leader

glenn12345

glenn12345 (99.95) Score: +161.22

The Score Leader is the player with the highest score across all their picks in TROV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Eric2204 99.42 8/20/2012 Underperform 5Y $2.35 -65.85% +80.40% +146.24 0 Comment
GSLogan 88.73 9/20/2013 Underperform 1Y $7.03 -88.58% +49.83% +138.41 0 Comment
WSMOOT19 71.61 1/30/2017 Underperform 1Y $2.00 -59.87% +12.25% +72.12 0 Comment
Emilie111 99.98 10/6/2017 Underperform 5Y $0.80 +0.65% +0.79% +0.14 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. glenn12345 99.95 5/31/2017 Underperform 5Y $0.65 +23.48% +6.25% -17.22 0 Comment
gafftm14 56.54 5/3/2017 Outperform 5Y $0.91 -11.80% +7.48% -19.28 1 Comment
MBDixieBlue < 20 1/12/2017 Outperform 5Y $2.30 -65.10% +13.07% -78.18 0 Comment
return100 32.29 7/22/2016 Outperform 5Y $5.06 -84.14% +18.34% -102.48 0 Comment
Rider < 20 6/14/2016 Outperform 5Y $4.13 -80.59% +23.71% -104.30 0 Comment
odocoileus 30.34 12/22/2014 Outperform 5Y $4.47 -82.04% +23.87% -105.92 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRothCapital 72.01 12/20/2012 Outperform NS $7.08 -88.66% +77.39% -166.05 0 Comment

Featured Broker Partners